Integra Lifesciences Holdings CORP Form 4 insider transactions

Jeffrey Mosebrook, SVP of Integra Lifesciences, reported a transaction involving the acquisition of common stock.

Harvinder Singh, EVP & President, SS at Integra LifeSciences Holdings Corp, was granted 5,590 restricted stock units.

Robert T. Davis Jr., EVP & President of TR&DT at Integra LifeSciences, was granted 11,180 restricted stock units.

Michael J. McBreen, EVP & Chief Commercial Officer at Integra LifeSciences Holdings Corp., was granted stock options and restricted stock units.

Integra Lifesciences Holdings Corp. reports the grant of stock options and restricted stock units to President and CEO Stuart Essig, with vesting schedules tied to continued service.

Barbara B. Hill, a Director at Integra LifeSciences Holdings Corp. (IART), reported the acquisition of 6,638 and 17,700 shares of common stock on May 7, 2026.

Integra LifeSciences Holdings Corp. Director Keith Bradley acquired 17,700 restricted stock units and disposed of 88,254 shares.

Integra Lifesciences Holdings Corp. reports a grant of restricted stock units to Director Shaundra Clay, vesting in one year.

Integra LifeSciences Holdings Corp. reports a grant of 17,700 Restricted Stock Units (RSUs) to Director Jeffrey A. Graves.

Director Renee Wonlai Lo received a grant of 17,700 restricted stock units (RSUs) from Integra Lifesciences Holdings Corp.

Christian S. Schade, a Director at Integra Lifesciences Holdings Corp., was granted 17,700 Restricted Stock Units (RSUs) on May 7, 2026, vesting one year later.

Harvinder Singh, EVP & President, International, reported multiple acquisitions and dispositions of Integra LifeSciences common stock and restricted stock units.

Integra LifeSciences EVP Michael McBreen reported the acquisition of 92,108 restricted stock units and the disposition of 9,601 common shares for tax purposes.

Integra LifeSciences EVP Robert T. Davis Jr. reported the acquisition of 43,350 restricted stock units and the disposal of 9,174 common shares for tax purposes.

Jeffrey Mosebrook, SVP of Finance at Integra LifeSciences, reported the acquisition of restricted stock units and disposition of common stock.

Integra LifeSciences EVP & CFO Lea Daniels Knight reported the acquisition of 111,179 restricted stock units and the disposition of 8,089 common shares for tax purposes.

Integra LifeSciences Holdings Corp's EVP & CHRO, Chantal Veillon-Berteloot, was granted 41,783 Restricted Stock Units and disposed of 5,420 common shares.

Integra LifeSciences Holdings Corp's President and CEO, Mojdeh Poul, acquired 343,393 restricted stock units, vesting over three years.

Integra LifeSciences Holdings Corp. granted its EVP, Chief Legal Officer & Secretary, Michael Damon Hutchinson, 70,305 restricted stock units with a future vesting schedule.

Integra LifeSciences Holdings Corp.'s EVP, Chief Legal Officer, Michael Hutchinson, was granted 89,606 restricted stock units.

Integra LifeSciences CEO Mojdeh Poul reported the vesting of restricted stock units and subsequent tax-related dispositions.

Jeffrey A. Graves, a director at Integra Lifesciences Holdings Corp., purchased 9,000 shares of common stock for $11.35 per share.

Harvinder Singh, EVP & President, International at Integra LifeSciences, reported the vesting of 11,965 restricted stock units and a subsequent sale of 3,281 shares for tax obligations.

Integra LifeSciences Holdings Corp's EVP & CHRO, Chantal Veillon-Berteloot, reported the disposition of 3,551 shares of common stock for tax withholding purposes.

Integra LifeSciences Director Stuart Essig reported changes in his beneficial ownership, including transfers to a grantor trust and distributions from grantor retained annuity trusts.

Integra LifeSciences Holdings Corp's Executive Vice President and Chief Financial Officer, Lea Daniels Knight, disposed of 2,561 shares of common stock to cover tax withholding obligations.

Jeffrey Mosebrook, SVP, Fin & Princ Acct Officer at Integra LifeSciences Holdings Corp, disposed of 3,345 shares of common stock to cover tax withholding obligations.

Jeffrey Mosebrook, SVP, Finance & Principal Accounting Officer at Integra LifeSciences Holdings Corp, disposed of 937 shares of common stock on July 1, 2025, to cover tax withholding obligations.

Director Keith Bradley reports a transaction involving Integra LifeSciences Holdings Corp. stock, including the acquisition and disposal of shares.

Director Jeffrey Graves reports acquisition and disposal of common stock in Integra LifeSciences Holdings Corp.